Company Profile

Providers are faced with a myriad of existing payers, and simplifying the understanding of authorization criteria for all stakeholders is a priority, especially as it relates to complex therapies with restricted uses.
Beyond providing a potential treatment for a range of serious illnesses, Pluristem has developed a technology that may have unlocked the future for stem cell manufacturing in the pharmaceutical industry.
Gilead has recently been on the radar in the specialty pharmacy world for a key business move in the industry-the acquisition of Pharmasset. Pharmasset became a wholly-owned subsidiary of Gilead Sciences, Inc on January 17, 2012.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2017
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$